Landos Biopharma Price Prediction
| LABPDelisted Stock | USD 4.02 0.15 3.60% |
Oversold Vs Overbought
61
Oversold | Overbought |
Using Landos Biopharma hype-based prediction, you can estimate the value of Landos Biopharma from the perspective of Landos Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Landos Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Landos because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Landos Biopharma after-hype prediction price | USD 4.02 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Landos |
Landos Biopharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Landos Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Landos Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Landos Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Landos Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Landos Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Landos Biopharma's historical news coverage. Landos Biopharma's after-hype downside and upside margins for the prediction period are 4.02 and 4.02, respectively. We have considered Landos Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Landos Biopharma is very steady at this time. Analysis and calculation of next after-hype price of Landos Biopharma is based on 3 months time horizon.
Landos Biopharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Landos Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Landos Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Landos Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 1 Events / Month | 5 Events / Month | Very soon |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
4.02 | 4.02 | 0.00 |
|
Landos Biopharma Hype Timeline
Landos Biopharma is now traded for 4.02. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Landos is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at 0.0%. %. The volatility of related hype on Landos Biopharma is about 0.0%, with the expected price after the next announcement by competition of 4.02. About 52.0% of the company shares are owned by institutional investors. The book value of Landos Biopharma was now reported as 7.43. The company recorded a loss per share of 4.0. Landos Biopharma had not issued any dividends in recent years. The entity had 1:10 split on the 26th of May 2023. Given the investment horizon of 90 days the next forecasted press release will be very soon. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.Landos Biopharma Related Hype Analysis
Having access to credible news sources related to Landos Biopharma's direct competition is more important than ever and may enhance your ability to predict Landos Biopharma's future price movements. Getting to know how Landos Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Landos Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| EFTR | Effector Therapeutics | (0.06) | 4 per month | 0.00 | (0.31) | 8.70 | (27.78) | 88.91 | |
| APGN | Apexigen | (0.02) | 5 per month | 5.50 | (0) | 7.89 | (11.11) | 58.79 | |
| NAVB | Navidea Biopharmaceuticals | 0.00 | 0 per month | 0.00 | (0.15) | 12.50 | (12.50) | 40.40 | |
| ANGN | Angion Biomedica Corp | 6.76 | 3 per month | 5.44 | 0.11 | 11.55 | (7.70) | 42.18 | |
| ONCR | Oncorus | 0.01 | 3 per month | 0.00 | (0.16) | 10.00 | (21.20) | 120.67 | |
| APLM | Apollomics Class A | (1.90) | 2 per month | 7.65 | 0.01 | 9.07 | (9.17) | 134.75 | |
| CDIO | Cardio Diagnostics Holdings | (0.01) | 3 per month | 6.76 | (0.01) | 14.81 | (13.16) | 57.04 | |
| RNAZ | Transcode Therapeutics | (0.02) | 4 per month | 6.97 | 0.06 | 22.00 | (11.43) | 68.80 | |
| NEXI | Neximmune | 0.00 | 0 per month | 0.00 | (0.04) | 5.90 | (9.00) | 94.30 | |
| XBIO | Xenetic Biosciences | (0.24) | 7 per month | 4.24 | 0.04 | 7.65 | (7.09) | 26.99 |
Landos Biopharma Additional Predictive Modules
Most predictive techniques to examine Landos price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Landos using various technical indicators. When you analyze Landos charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Landos Biopharma Predictive Indicators
The successful prediction of Landos Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Landos Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Landos Biopharma based on analysis of Landos Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Landos Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Landos Biopharma's related companies.
Story Coverage note for Landos Biopharma
The number of cover stories for Landos Biopharma depends on current market conditions and Landos Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Landos Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Landos Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Landos Biopharma Short Properties
Landos Biopharma's future price predictability will typically decrease when Landos Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Landos Biopharma often depends not only on the future outlook of the potential Landos Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Landos Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 6.3 M | |
| Cash And Short Term Investments | 37.5 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Landos Stock
If you are still planning to invest in Landos Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Landos Biopharma's history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |